J&J $5.5B Talc Settlement; Merck KEYTRUDA Wins Phase 3

Merck ($MRK) reported that KEYTRUDA met its primary endpoint of progression-free survival in the Phase 3 KEYNOTE C93 trial for advanced or recurrent endometrial cancer, marking the first time a PD-1 inhibitor has demonstrated statistically significant benefit over platinum chemotherapy in this patient population. $MRK shares rose 5.4% on the development, which represents a potentially significant expansion of the blockbuster oncology franchise. The company also secured U.S. FDA approval for LIPFENDRA, the first oral PCSK9 inhibitor for lowering LDL cholesterol, and announced a royalty-free licensing deal with Aurobindo Pharma to supply generic alimatravir for HIV prevention across 129 low- and middle-income countries. Moderna ($MRNA) closed at $55.63, up 2.89%, with shares having soared nearly 90% thus far in 2026 following positive news surrounding one of its vaccines. Eli Lilly ($LLY) continued to attract investor attention as analysts highlighted its sustainable growth profile and strong fundamentals despite a relatively low dividend yield.

Intuitive Surgical ($ISRG) shares jumped 5.3% after announcing a collaboration with Deion "Coach Prime" Sanders to raise patient awareness of its da Vinci robotic-assisted surgery systems, with the partnership aiming to increase understanding of different surgical options available to patients and encourage informed conversations between patients and their doctors. Abbott Laboratories ($ABT) secured exclusive U.S. commercialization rights for Freenome's SimpleScreen CRC, a newly FDA-approved blood-based colorectal cancer screening test, expanding the company's presence in the colorectal cancer screening category within its broader diagnostics portfolio. $ABT delivered strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating quarterly estimates and prompting the company to raise its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes.

Johnson & Johnson ($JNJ) has offered to pay up to $5.5 billion to resolve tens of thousands of lawsuits in the U.S. alleging its talcum powder caused ovarian cancer, with the settlement covering approximately 76,000 claims. The company has already settled most cases alleging its talc contained asbestos and caused mesothelioma. $JNJ's vice president of litigation, Erik Haas, said the move was motivated by a desire to get closure, describing the claims themselves as "meritless." The proposed settlement represents one of the largest product liability resolutions in the healthcare sector and could provide clarity for investors regarding the company's future exposure to talc-related litigation.

UnitedHealth Group ($UNH) and Intuitive Surgical ($ISRG) reported earnings the same week in July, with both companies beating Wall Street expectations but experiencing divergent market reactions. One stock jumped as much as 8% while the other fell as much as 13%, illustrating how earnings beats alone are insufficient to drive positive stock performance in the current healthcare environment. $UNH experienced a post-earnings pullback following a 52-week high, as stronger guidance offset Medicaid pressures. The contrasting market responses highlight investor focus on forward guidance quality, segment mix, and operational execution rather than simply meeting or beating consensus estimates.

Scribe Therapeutics shares are up 30% since the company raised $125 million in its initial public offering Friday, with the cash intended to fund three clinical trials testing whether Scribe's one-time treatments can halve the risk of heart attacks and strokes. The company's therapies aim to turn off the genetic instructions leading to high levels of damaging lipids without having to cut a gene's DNA strands like other one-shot genetic treatments currently in the clinic. The IPO and subsequent share performance reflect continued investor appetite for novel genetic editing platforms targeting high-prevalence cardiovascular conditions. The strong debut positions Scribe to advance its clinical pipeline and compete in the emerging field of genetic medicines for lipid management alongside established players.